Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
-
BUSINESS Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
-
BUSINESS Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
-
REGULATORY Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
-
BUSINESS Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
-
REGULATORY Gilead’s Sofosbuvir Could Join NHI Price List in May If OK’ed by PAFSC Panel on March 5
February 20, 2015
-
REGULATORY Chuikyo Approves 26 Products Including Takecab, Zelboraf for Listing
February 19, 2015
-
BUSINESS Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
-
REGULATORY Abe Calls for Shrewd Strategies for Pharmas, Industry Consolidation as Necessary
February 18, 2015
-
BUSINESS Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
-
BUSINESS Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
-
BUSINESS GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
-
BUSINESS Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
-
BUSINESS Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
-
REGULATORY MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
-
ACADEMIA Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
-
ORGANIZATION PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
-
REGULATORY NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
-
BUSINESS Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
-
REGULATORY MHLW Plans Business Suspension Order for Novartis
February 5, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…